ARTICLES
FDA Grants Priority Review to Bevacizumab in Ovarian Cancer
The FDA has assigned a priority review designation to bevacizumab (Avastin) in combination with chemotherapy for patients with recurrent platinum-resistant ovarian cancer.
Lanreotide Prolongs PFS in Patients With Gastroenteropancreatic NETs
The somatostatin analog lanreotide (Somatuline Depot) significantly prolonged progression-free survival (PFS) compared with placebo for patients with metastatic gastroenteropancreatic NETs.
Bevacizumab Receives Priority Review for Advanced Cervical Cancer
The FDA has assigned a priority review designation to bevacizumab (Avastin) plus chemotherapy as a treatment for patients with persistent, recurrent, or metastatic cervical cancer.
Dabrafenib/Trametinib Combo Study Stopped Early Following Positive Interim Analysis
A phase III study comparing trametinib (Mekinist) plus dabrafenib (Tafinlar) with single-agent vemurafenib (Zelboraf) has been stopped early following a positive interim analysis.